title: Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases.
abstract: Intracranial ependymomas are the third most common primary brain tumor in children. A variety of chemotherapy protocols have been introduced for the treatment of ependymoma although overall these have not contributed to patients outcome. To our knowledge, data on the prognostic value of immunoexpression of the chemoresistance-related proteins (ChRPs) in ependymomas are absent. Seventy-six patients with intracranial ependymomas who received combined treatment were studied retrospectively. Tumor specimens were immunohistochemically examined with antibodies to metallothioneins (MT), glutathione S-transferase pi (GST pi) and P-glycoprotein (P-GP). The results demonstrated significant preponderance of expression of all the above-mentioned ChRPs for the low-grade tumors. The progression-free survival time was found to be significantly shorter for immunonegative tumors in both tumor grades. Multivariate analysis using a Cox hazard model revealed that recurrence-free survival time is significantly associated with tumor grade, and MT and P-GP expression. Risk of recurrence increased for the high-grade ependymomas (hazard ratio 2.85; P = 0.004), and decreased for the MT-positive tumors (hazard ratio -2.72; P = 0.005) and for the P-GP-positive tumors (hazard ratio -2.02; P = 0.02). The obtained results allow one to conclude that ChRPs expression is closely associated with low-grade ependymomas and immunohistochemical findings may be estimated as a predictor for local tumor progression.
authors.affiliation: Department of Neuropathology, Neurosurgical NN Burdenko Institute, Moscow, Russia. akorshunov@nsi.ru
authors.forename: A
authors.initials: A
authors.lastname: Korshunov
authors.forename: R
authors.initials: R
authors.lastname: Sycheva
authors.forename: V
authors.initials: V
authors.lastname: Timirgaz
authors.forename: A
authors.initials: A
authors.lastname: Golanov
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000032:analysis* / Q000276:immunology; D000293:Adolescent; D000328:Adult; D001932:Brain Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D002648:Child; D019008:Drug Resistance, Neoplasm; D004805:Ependyma / Q000737:chemistry / Q000201:enzymology; D004806:Ependymoma / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D005982:Glutathione Transferase / Q000032:analysis* / Q000276:immunology; D006801:Humans; D008297:Male; D008668:Metallothionein / Q000032:analysis* / Q000276:immunology; D009364:Neoplasm Recurrence, Local; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D008668:Metallothionein; D005982:Glutathione Transferase